XML 13 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating Expenses:        
Research and development $ 4,329 $ 1,818 $ 9,405 $ 3,317
General and administrative 2,818 2,474 5,828 5,032
Total operating expenses 7,147 4,292 15,233 8,349
Operating loss (7,147) (4,292) (15,233) (8,349)
Other income (expense):        
Investment income, net 47 22 70 93
Other expense, net (90) 0 (90) 0
Total other (expense) income (43) 22 (20) 93
Net loss before benefit from income taxes and noncontrolling interests (7,190) (4,270) (15,253) (8,256)
Benefit from income taxes (1,508) (10,872) (1,508) (10,872)
Net (loss) income (5,682) 6,602 (13,745) 2,616
Less - net income attributable to noncontrolling interests 0 4 0 8
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders $ (5,682) $ 6,598 $ (13,745) $ 2,608
Basic and diluted (loss) income per share        
Caladrius Biosciences, Inc. common stockholders - basic (in usd per share) $ (0.10) $ 0.50 $ (0.27) $ 0.22
Caladrius Biosciences, Inc. common stockholders - diluted (in usd per share) $ (0.10) $ 0.50 $ (0.27) $ 0.22
Weighted average common shares outstanding        
Basic shares 59,510 13,151 50,862 11,880
Diluted shares 59,510 13,151 50,862 11,880